The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: Results of a two-stage, controlled phase II study.
Andres Poveda
Honoraria - PharmaMar
Dominique Berton-Rigaud
No relevant relationships to disclose
Isabelle Laure Ray-Coquard
Consultant or Advisory Role - PharmaMar; Roche
Honoraria - PharmaMar; Roche
Jérôme Alexandre
Honoraria - PharmaMar
Magali Provansal
No relevant relationships to disclose
Arturo Soto
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Carmen Maria Kahatt
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Sergio A. Szyldergemajn
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Antonio Nieto
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Cristian Fernandez
Employment or Leadership Position - PharmaMar
Stock Ownership - PaarmaMar
Eva Guerra Alia
No relevant relationships to disclose
Antonio Casado
No relevant relationships to disclose
Antonio Gonzalez-Martin
Consultant or Advisory Role - PharmaMar
Jose Maria Del Campo
No relevant relationships to disclose